Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
26 Octobre 2023 - 3:05PM
Business Wire
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing
novel immunological agents to treat various cancers, today
announced the Company will release its third quarter 2023 financial
results via press release before the market opens on Tuesday,
November 7, 2023.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026932669/en/
Investor 917-362-1370
investors@agenusbio.com
Media 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Agenus (NASDAQ:AGEN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024